{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-000092","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.818769+00:00","generated_at":"2026-05-28T18:08:32.804200+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Karyopharm appoints Lori Macomber as CFO effective Jan 3, 2025","bullets":["Macomber previously CFO at Legend Biotech, will serve as EVP, CFO and Treasurer.","Annual base salary of $475,000; target annual bonus of 45% of base salary.","Inducement equity: option for 650,000 shares and 160,000 RSUs, vesting over 4 and 3 years.","Kristin Abate, interim principal financial officer, will step down on Jan 3, 2025.","Severance includes one month base salary per month of service (max 12 months), enhanced upon change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-000092","json":"https://secwatch.observer/filing/0000950170-25-000092.json","markdown":"https://secwatch.observer/filing/0000950170-25-000092.md","text":"https://secwatch.observer/filing/0000950170-25-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025000092/0000950170-25-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025000092/kpti-20250102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T18:08:32.804200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}